Drug intelligence / Profile preview

TNX-1850

Development stage
Discontinued
Lead developer
Tonix Pharmaceuticals
Modality
Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Percutaneous (bifurcated Needle)
01

Overview

TNX-1850 is a live virus vaccine candidate developed by Tonix Pharmaceuticals for the prevention of COVID-19. It is based on a recombinant horsepox virus vector engineered to express the spike protein from the SARS-CoV-2 BA.2 variant. The platform leverages the large packaging capacity and strong immunogenicity of horsepox-based vectors, aiming to induce robust T cell responses against SARS-CoV-2. This approach builds on prior work with related candidates such as TNX-1800 (expressing Wuhan strain spike) and is designed for percutaneous administration using a bifurcated needle, similar to historical smallpox vaccination methods[1][3][7]. As of 2024, development status appears discontinued[2].

Brand names
TNX-1850TNX1850TNX 1850
Other names
TNX-1850TNX1850TNX 1850
02

Targets

BA.2 S (SARS-CoV-2 BA.2 spike protein)SARS-CoV-2 spike

Beyond the preview

Go deeper on TNX-1850.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-1850.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call